-+ 0.00%
-+ 0.00%
-+ 0.00%

TEVA: TEVA TO OBTAIN U.S. COMMERCIALIZATION RIGHTS FOR TWO IMMUNOLOGY BIOSIMILARS: ETICOVO UPON CLOSE AND INFLIXIMAB-ABDA IN Q3 2027

Reuters·11/03/2026 10:03:04